Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes and obesity, respectively.
Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.
1don MSNOpinion
The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...
Hims & Hers, a San Francisco-headquartered telehealth company, ran its controversial Super Bowl commercial despite multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback